| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Shock, Septic | 13 | 2019 | 1313 | 2.51 | Why? |
| Adrenal Insufficiency | 6 | 2018 | 190 | 2.42 | Why? |
| Adrenal Cortex Hormones | 20 | 2021 | 6537 | 2.00 | Why? |
| Hydrocortisone | 11 | 2021 | 1790 | 1.95 | Why? |
| Muscular Dystrophy, Duchenne | 3 | 2018 | 129 | 1.86 | Why? |
| Fludrocortisone | 2 | 2018 | 10 | 1.51 | Why? |
| Plasma Substitutes | 2 | 2018 | 24 | 1.50 | Why? |
| Pituitary-Adrenal System | 3 | 2017 | 135 | 1.48 | Why? |
| Vasoconstrictor Agents | 6 | 2018 | 714 | 1.47 | Why? |
| Sepsis | 13 | 2019 | 3517 | 1.38 | Why? |
| Shock | 5 | 2020 | 1868 | 1.29 | Why? |
| Receptors, Glucocorticoid | 3 | 2021 | 118 | 1.18 | Why? |
| Vasopressins | 2 | 2018 | 70 | 1.05 | Why? |
| Leucine Zippers | 1 | 2021 | 18 | 0.95 | Why? |
| Colloids | 2 | 2018 | 49 | 0.94 | Why? |
| Carbon Monoxide Poisoning | 2 | 2017 | 24 | 0.84 | Why? |
| Critical Illness | 23 | 2021 | 17281 | 0.83 | Why? |
| Neuromuscular Diseases | 3 | 2018 | 303 | 0.79 | Why? |
| Neurophysins | 1 | 2018 | 5 | 0.76 | Why? |
| Drug Recalls | 1 | 2018 | 5 | 0.75 | Why? |
| Hydroxyethyl Starch Derivatives | 1 | 2018 | 22 | 0.73 | Why? |
| Anti-Inflammatory Agents | 6 | 2020 | 6153 | 0.70 | Why? |
| Dopamine | 2 | 2018 | 123 | 0.68 | Why? |
| Carboxyhemoglobin | 1 | 2017 | 34 | 0.67 | Why? |
| Protein Precursors | 2 | 2018 | 425 | 0.67 | Why? |
| Norepinephrine | 2 | 2018 | 152 | 0.67 | Why? |
| Respiration, Artificial | 20 | 2021 | 22116 | 0.65 | Why? |
| Bundle-Branch Block | 1 | 2018 | 127 | 0.65 | Why? |
| Hypothalamo-Hypophyseal System | 1 | 2017 | 187 | 0.62 | Why? |
| Conflict of Interest | 1 | 2018 | 175 | 0.61 | Why? |
| Carbon Monoxide | 1 | 2017 | 167 | 0.60 | Why? |
| Death | 1 | 2018 | 334 | 0.56 | Why? |
| Diaphragm | 1 | 2018 | 232 | 0.56 | Why? |
| Critical Care | 10 | 2021 | 14081 | 0.55 | Why? |
| Coma | 1 | 2016 | 204 | 0.54 | Why? |
| Protein C | 1 | 2014 | 141 | 0.52 | Why? |
| Advisory Committees | 5 | 2018 | 1418 | 0.51 | Why? |
| Hyperbaric Oxygenation | 1 | 2017 | 268 | 0.51 | Why? |
| Body Temperature | 1 | 2018 | 875 | 0.47 | Why? |
| Hypnotics and Sedatives | 1 | 2017 | 624 | 0.44 | Why? |
| Muscle, Skeletal | 1 | 2018 | 915 | 0.43 | Why? |
| Clinical Trials, Phase II as Topic | 1 | 2014 | 801 | 0.43 | Why? |
| Meta-Analysis as Topic | 1 | 2018 | 1289 | 0.43 | Why? |
| Stroke Volume | 2 | 2018 | 2153 | 0.41 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2014 | 782 | 0.41 | Why? |
| Organ Dysfunction Scores | 5 | 2021 | 1475 | 0.39 | Why? |
| Resuscitation | 4 | 2018 | 638 | 0.38 | Why? |
| Immunomodulation | 1 | 2018 | 1472 | 0.38 | Why? |
| Home Care Services | 2 | 2018 | 1351 | 0.38 | Why? |
| Glucocorticoids | 3 | 2020 | 4431 | 0.38 | Why? |
| Respiratory Insufficiency | 7 | 2020 | 7301 | 0.37 | Why? |
| Endocrine Glands | 1 | 2008 | 36 | 0.36 | Why? |
| Myotonic Dystrophy | 2 | 2018 | 51 | 0.35 | Why? |
| Fluid Therapy | 4 | 2018 | 628 | 0.31 | Why? |
| Systemic Inflammatory Response Syndrome | 4 | 2018 | 6653 | 0.29 | Why? |
| Oxygen | 1 | 2018 | 3715 | 0.27 | Why? |
| Hormones | 2 | 2017 | 66 | 0.26 | Why? |
| Humans | 84 | 2021 | 930598 | 0.26 | Why? |
| Ventilator Weaning | 2 | 2020 | 536 | 0.26 | Why? |
| France | 10 | 2021 | 12074 | 0.25 | Why? |
| Survival Analysis | 8 | 2021 | 7592 | 0.25 | Why? |
| Genetic Predisposition to Disease | 1 | 2018 | 4027 | 0.25 | Why? |
| Fibrinolytic Agents | 1 | 2014 | 1702 | 0.24 | Why? |
| Intensive Care Units | 16 | 2021 | 29594 | 0.22 | Why? |
| Ritonavir | 3 | 2021 | 4212 | 0.22 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.22 | Why? |
| Heart Diseases | 1 | 2018 | 3503 | 0.22 | Why? |
| Diet, Protein-Restricted | 1 | 2021 | 80 | 0.21 | Why? |
| Renal Replacement Therapy | 3 | 2018 | 1530 | 0.21 | Why? |
| Anti-Bacterial Agents | 7 | 2018 | 10083 | 0.20 | Why? |
| Practice Guidelines as Topic | 4 | 2018 | 15421 | 0.20 | Why? |
| Treatment Outcome | 13 | 2021 | 51732 | 0.20 | Why? |
| Bacterial Infections | 3 | 2018 | 2229 | 0.20 | Why? |
| Paresis | 1 | 2020 | 77 | 0.20 | Why? |
| Anti-Glomerular Basement Membrane Disease | 1 | 2019 | 31 | 0.20 | Why? |
| Mineralocorticoids | 1 | 2018 | 4 | 0.19 | Why? |
| Furans | 1 | 2020 | 156 | 0.19 | Why? |
| Hemodynamics | 2 | 2018 | 1562 | 0.19 | Why? |
| Sarcoglycanopathies | 1 | 2018 | 3 | 0.19 | Why? |
| Calcitonin | 2 | 2017 | 201 | 0.19 | Why? |
| Dobutamine | 1 | 2018 | 36 | 0.19 | Why? |
| Neuroendocrine Cells | 1 | 2017 | 9 | 0.18 | Why? |
| Cosyntropin | 1 | 2017 | 9 | 0.18 | Why? |
| Volatile Organic Compounds | 1 | 2020 | 187 | 0.18 | Why? |
| Receptors, Mineralocorticoid | 1 | 2017 | 15 | 0.18 | Why? |
| Heparin | 2 | 2021 | 2600 | 0.18 | Why? |
| Simplified Acute Physiology Score | 1 | 2018 | 102 | 0.18 | Why? |
| Corpus Callosum | 1 | 2020 | 182 | 0.18 | Why? |
| Triazines | 1 | 2020 | 246 | 0.18 | Why? |
| Prognosis | 9 | 2021 | 32490 | 0.18 | Why? |
| Randomized Controlled Trials as Topic | 9 | 2020 | 10649 | 0.17 | Why? |
| Clinical Studies as Topic | 1 | 2018 | 118 | 0.17 | Why? |
| Adult | 28 | 2021 | 244371 | 0.17 | Why? |
| Adrenocorticotropic Hormone | 1 | 2017 | 107 | 0.17 | Why? |
| Sulfones | 1 | 2017 | 66 | 0.17 | Why? |
| Thoracic Wall | 1 | 2017 | 54 | 0.17 | Why? |
| Isotonic Solutions | 1 | 2017 | 69 | 0.17 | Why? |
| Lopinavir | 3 | 2021 | 4308 | 0.17 | Why? |
| Male | 41 | 2021 | 367725 | 0.17 | Why? |
| Hypoventilation | 1 | 2016 | 17 | 0.17 | Why? |
| Evoked Potentials | 1 | 2017 | 44 | 0.17 | Why? |
| Muscular Dystrophies | 1 | 2017 | 22 | 0.17 | Why? |
| Length of Stay | 7 | 2021 | 11042 | 0.17 | Why? |
| Regional Blood Flow | 1 | 2018 | 172 | 0.17 | Why? |
| Embolism, Air | 1 | 2017 | 23 | 0.17 | Why? |
| Pyrroles | 1 | 2020 | 292 | 0.17 | Why? |
| Spectroscopy, Near-Infrared | 1 | 2018 | 137 | 0.16 | Why? |
| Chromatography, Liquid | 1 | 2020 | 640 | 0.16 | Why? |
| Muscle Weakness | 1 | 2020 | 406 | 0.16 | Why? |
| Aldosterone | 1 | 2017 | 155 | 0.16 | Why? |
| Echocardiography, Doppler | 1 | 2018 | 269 | 0.16 | Why? |
| Female | 37 | 2021 | 380317 | 0.16 | Why? |
| Brain Stem | 1 | 2017 | 131 | 0.16 | Why? |
| Brain Death | 1 | 2018 | 146 | 0.15 | Why? |
| Epinephrine | 1 | 2018 | 323 | 0.15 | Why? |
| Deep Sedation | 1 | 2017 | 121 | 0.15 | Why? |
| Heart Failure | 1 | 2017 | 6638 | 0.15 | Why? |
| Consciousness Disorders | 1 | 2018 | 335 | 0.15 | Why? |
| Hypercapnia | 1 | 2016 | 172 | 0.15 | Why? |
| Chest Tubes | 1 | 2017 | 177 | 0.15 | Why? |
| Drug Therapy | 1 | 2018 | 280 | 0.15 | Why? |
| Middle Aged | 33 | 2021 | 270681 | 0.14 | Why? |
| Myasthenia Gravis | 1 | 2021 | 385 | 0.14 | Why? |
| Greece | 1 | 2021 | 2091 | 0.14 | Why? |
| Spirometry | 1 | 2018 | 524 | 0.14 | Why? |
| Metabolomics | 1 | 2020 | 921 | 0.14 | Why? |
| Hospital Mortality | 10 | 2021 | 22087 | 0.14 | Why? |
| Evidence-Based Medicine | 2 | 2018 | 3228 | 0.14 | Why? |
| Tandem Mass Spectrometry | 1 | 2020 | 1031 | 0.14 | Why? |
| Retrospective Studies | 15 | 2021 | 105322 | 0.13 | Why? |
| Aged | 28 | 2021 | 215776 | 0.13 | Why? |
| Europe | 4 | 2018 | 12702 | 0.13 | Why? |
| Iatrogenic Disease | 1 | 2017 | 304 | 0.13 | Why? |
| Patient Outcome Assessment | 1 | 2018 | 707 | 0.13 | Why? |
| Metabolic Diseases | 1 | 2019 | 505 | 0.13 | Why? |
| Methylprednisolone | 3 | 2020 | 2107 | 0.13 | Why? |
| Prospective Studies | 9 | 2021 | 43301 | 0.13 | Why? |
| Treatment Failure | 4 | 2021 | 2106 | 0.13 | Why? |
| Infusions, Intravenous | 1 | 2017 | 1224 | 0.13 | Why? |
| Stress, Physiological | 1 | 2017 | 378 | 0.13 | Why? |
| Gram-Negative Bacteria | 1 | 2018 | 473 | 0.13 | Why? |
| Severity of Illness Index | 7 | 2021 | 48226 | 0.12 | Why? |
| Mesenteric Ischemia | 1 | 2015 | 128 | 0.12 | Why? |
| Hospital Units | 1 | 2020 | 1017 | 0.12 | Why? |
| Receptors, Interleukin-6 | 1 | 2021 | 1383 | 0.12 | Why? |
| Respiration | 1 | 2018 | 729 | 0.12 | Why? |
| Gram-Negative Bacterial Infections | 1 | 2018 | 398 | 0.12 | Why? |
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 800 | 0.12 | Why? |
| Terminology as Topic | 1 | 2018 | 546 | 0.12 | Why? |
| Acute Disease | 4 | 2018 | 6029 | 0.12 | Why? |
| Nitriles | 1 | 2017 | 1053 | 0.12 | Why? |
| Stress Disorders, Post-Traumatic | 2 | 2020 | 2963 | 0.12 | Why? |
| Airway Extubation | 1 | 2017 | 403 | 0.12 | Why? |
| Drug Monitoring | 1 | 2020 | 1408 | 0.12 | Why? |
| Oximetry | 1 | 2017 | 658 | 0.12 | Why? |
| Amyotrophic Lateral Sclerosis | 1 | 2017 | 398 | 0.12 | Why? |
| Brain Injuries | 1 | 2017 | 374 | 0.11 | Why? |
| Electroencephalography | 1 | 2018 | 1242 | 0.11 | Why? |
| Ventilators, Mechanical | 3 | 2020 | 2193 | 0.11 | Why? |
| Research Design | 2 | 2018 | 5830 | 0.11 | Why? |
| Campylobacter jejuni | 1 | 2010 | 27 | 0.11 | Why? |
| Patients | 1 | 2018 | 1167 | 0.11 | Why? |
| Gastrointestinal Hemorrhage | 1 | 2017 | 669 | 0.11 | Why? |
| Signal Transduction | 2 | 2017 | 7207 | 0.11 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.10 | Why? |
| Campylobacter Infections | 1 | 2010 | 37 | 0.10 | Why? |
| Double-Blind Method | 2 | 2020 | 5988 | 0.10 | Why? |
| Personnel, Hospital | 2 | 2021 | 2273 | 0.10 | Why? |
| Cause of Death | 3 | 2020 | 4823 | 0.10 | Why? |
| Anticoagulants | 2 | 2021 | 9563 | 0.10 | Why? |
| Delirium | 1 | 2020 | 1061 | 0.10 | Why? |
| Clinical Trials as Topic | 2 | 2019 | 7330 | 0.10 | Why? |
| Academic Medical Centers | 1 | 2021 | 3088 | 0.09 | Why? |
| Antidiuretic Agents | 1 | 2008 | 14 | 0.09 | Why? |
| Survival Rate | 3 | 2020 | 9206 | 0.09 | Why? |
| Thrombosis | 2 | 2021 | 7504 | 0.09 | Why? |
| Immunoglobulins, Intravenous | 1 | 2021 | 2705 | 0.09 | Why? |
| Ventricular Function, Left | 1 | 2018 | 1555 | 0.09 | Why? |
| Blood Transfusion | 1 | 2018 | 1399 | 0.09 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.09 | Why? |
| Anti-Infective Agents | 1 | 2020 | 1766 | 0.09 | Why? |
| Cardiomyopathies | 1 | 2018 | 997 | 0.09 | Why? |
| Brain Diseases | 1 | 2020 | 1463 | 0.09 | Why? |
| Heart | 1 | 2018 | 1791 | 0.09 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.09 | Why? |
| Patient Compliance | 1 | 2018 | 1468 | 0.09 | Why? |
| Wounds and Injuries | 2 | 2018 | 1708 | 0.09 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.09 | Why? |
| Bacteriological Techniques | 1 | 2010 | 239 | 0.09 | Why? |
| Early Termination of Clinical Trials | 2 | 2020 | 1256 | 0.08 | Why? |
| Hospitals, University | 1 | 2020 | 4173 | 0.08 | Why? |
| Time Factors | 4 | 2018 | 31397 | 0.08 | Why? |
| Young Adult | 5 | 2018 | 93724 | 0.08 | Why? |
| Heart Arrest | 1 | 2018 | 1239 | 0.08 | Why? |
| Drug Combinations | 3 | 2021 | 3852 | 0.08 | Why? |
| Follow-Up Studies | 4 | 2018 | 17020 | 0.08 | Why? |
| Respiratory Tract Infections | 2 | 2017 | 6817 | 0.08 | Why? |
| Drug Evaluation, Preclinical | 1 | 2018 | 3347 | 0.08 | Why? |
| Quality of Life | 2 | 2017 | 9820 | 0.08 | Why? |
| Gastrointestinal Microbiome | 1 | 2019 | 1961 | 0.08 | Why? |
| Carrier State | 1 | 2018 | 2100 | 0.08 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.07 | Why? |
| Emergency Medical Services | 2 | 2018 | 3557 | 0.07 | Why? |
| Noninvasive Ventilation | 1 | 2017 | 2329 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2021 | 3892 | 0.07 | Why? |
| Drug Therapy, Combination | 1 | 2018 | 7268 | 0.07 | Why? |
| Odds Ratio | 3 | 2021 | 5861 | 0.07 | Why? |
| Recombinant Proteins | 1 | 2014 | 3786 | 0.07 | Why? |
| Family | 1 | 2017 | 2909 | 0.06 | Why? |
| Child | 3 | 2017 | 70012 | 0.06 | Why? |
| Brain | 2 | 2018 | 5133 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 5277 | 0.06 | Why? |
| Biomarkers | 4 | 2018 | 23361 | 0.06 | Why? |
| Surgical Procedures, Operative | 1 | 2018 | 2662 | 0.06 | Why? |
| Comorbidity | 3 | 2021 | 34796 | 0.06 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.06 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.06 | Why? |
| Aged, 80 and over | 8 | 2021 | 88759 | 0.06 | Why? |
| Time-to-Treatment | 1 | 2018 | 5883 | 0.06 | Why? |
| Discriminant Analysis | 1 | 2020 | 170 | 0.05 | Why? |
| Population | 1 | 2020 | 114 | 0.05 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.05 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 3832 | 0.05 | Why? |
| Least-Squares Analysis | 1 | 2020 | 254 | 0.05 | Why? |
| Logistic Models | 3 | 2021 | 9089 | 0.05 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.05 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.05 | Why? |
| Hydroxychloroquine | 2 | 2021 | 12447 | 0.05 | Why? |
| Drug Stability | 1 | 2020 | 236 | 0.05 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.05 | Why? |
| Trinucleotide Repeat Expansion | 1 | 2018 | 9 | 0.05 | Why? |
| Myotonin-Protein Kinase | 1 | 2018 | 16 | 0.05 | Why? |
| Hypertension | 1 | 2021 | 8895 | 0.05 | Why? |
| Dexamethasone | 2 | 2020 | 2055 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.05 | Why? |
| Antiviral Agents | 3 | 2021 | 41703 | 0.05 | Why? |
| Tissue Distribution | 1 | 2020 | 483 | 0.05 | Why? |
| Hemorrhage | 2 | 2021 | 3013 | 0.05 | Why? |
| Animals | 4 | 2020 | 78931 | 0.05 | Why? |
| Nutritional Physiological Phenomena | 1 | 2019 | 100 | 0.05 | Why? |
| Prevalence | 2 | 2018 | 25773 | 0.05 | Why? |
| Cytokines | 2 | 2017 | 15010 | 0.05 | Why? |
| Principal Component Analysis | 1 | 2020 | 689 | 0.04 | Why? |
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 317 | 0.04 | Why? |
| Acute Kidney Injury | 1 | 2018 | 5762 | 0.04 | Why? |
| Reflex | 1 | 2017 | 22 | 0.04 | Why? |
| Calcitonin Gene-Related Peptide | 1 | 2017 | 52 | 0.04 | Why? |
| Motor Neuron Disease | 1 | 2017 | 45 | 0.04 | Why? |
| Hypoalbuminemia | 1 | 2020 | 235 | 0.04 | Why? |
| Endotoxins | 1 | 2017 | 80 | 0.04 | Why? |
| Biomedical Research | 1 | 2018 | 5270 | 0.04 | Why? |
| Breath Tests | 1 | 2020 | 338 | 0.04 | Why? |
| Paris | 1 | 2021 | 1287 | 0.04 | Why? |
| Hospital Design and Construction | 1 | 2020 | 287 | 0.04 | Why? |
| Energy Intake | 1 | 2019 | 323 | 0.04 | Why? |
| Adolescent | 2 | 2018 | 86841 | 0.04 | Why? |
| Guillain-Barre Syndrome | 1 | 2010 | 1495 | 0.04 | Why? |
| Neurophysiology | 1 | 2017 | 86 | 0.04 | Why? |
| Anxiety | 2 | 2020 | 17311 | 0.04 | Why? |
| Glasgow Coma Scale | 1 | 2017 | 249 | 0.04 | Why? |
| Vital Capacity | 1 | 2018 | 399 | 0.04 | Why? |
| Adenosine | 1 | 2020 | 509 | 0.04 | Why? |
| Africa, Northern | 1 | 2017 | 539 | 0.04 | Why? |
| Betacoronavirus | 7 | 2020 | 204454 | 0.04 | Why? |
| APACHE | 1 | 2018 | 682 | 0.04 | Why? |
| Disease-Free Survival | 1 | 2020 | 1654 | 0.04 | Why? |
| Disease Progression | 3 | 2020 | 13580 | 0.04 | Why? |
| Patients' Rooms | 1 | 2020 | 675 | 0.04 | Why? |
| Preliminary Data | 1 | 2017 | 457 | 0.04 | Why? |
| Polymerase Chain Reaction | 1 | 2010 | 6740 | 0.04 | Why? |
| Cross-Over Studies | 1 | 2018 | 867 | 0.03 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.03 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.03 | Why? |
| Aspartate Aminotransferases | 1 | 2021 | 1394 | 0.03 | Why? |
| Neurologic Examination | 1 | 2017 | 428 | 0.03 | Why? |
| History, 21st Century | 1 | 2021 | 1849 | 0.03 | Why? |
| Area Under Curve | 1 | 2020 | 2564 | 0.03 | Why? |
| Erythrocyte Transfusion | 1 | 2017 | 386 | 0.03 | Why? |
| Lipopolysaccharides | 1 | 2017 | 848 | 0.03 | Why? |
| Genotype | 2 | 2018 | 4697 | 0.03 | Why? |
| Grief | 1 | 2017 | 320 | 0.03 | Why? |
| Nutrition Assessment | 1 | 2017 | 527 | 0.03 | Why? |
| Kidney Failure, Chronic | 2 | 2019 | 3222 | 0.03 | Why? |
| Nutritional Support | 1 | 2017 | 447 | 0.03 | Why? |
| Ferritins | 1 | 2021 | 2055 | 0.03 | Why? |
| Limit of Detection | 1 | 2020 | 2698 | 0.03 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2021 | 1731 | 0.03 | Why? |
| Patient Care Planning | 1 | 2017 | 582 | 0.03 | Why? |
| Bayes Theorem | 1 | 2021 | 3237 | 0.03 | Why? |
| Down-Regulation | 1 | 2017 | 1416 | 0.03 | Why? |
| Respiratory Function Tests | 1 | 2018 | 1755 | 0.03 | Why? |
| Serotyping | 1 | 2010 | 154 | 0.03 | Why? |
| NF-kappa B | 1 | 2017 | 1301 | 0.03 | Why? |
| Multivariate Analysis | 1 | 2020 | 5440 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2021 | 4758 | 0.02 | Why? |
| Cognition | 1 | 2018 | 1394 | 0.02 | Why? |
| Bacterial Typing Techniques | 1 | 2010 | 273 | 0.02 | Why? |
| Pilot Projects | 1 | 2020 | 5182 | 0.02 | Why? |
| Hospitals, Teaching | 1 | 2017 | 1609 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Heart Rate | 1 | 2017 | 1527 | 0.02 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 1261 | 0.02 | Why? |
| Body Mass Index | 1 | 2020 | 4306 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.02 | Why? |
| Clinical Protocols | 1 | 2018 | 2734 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2017 | 5542 | 0.02 | Why? |
| Patient Isolation | 1 | 2020 | 3182 | 0.02 | Why? |
| Blood Pressure | 1 | 2017 | 2198 | 0.02 | Why? |
| Inflammation Mediators | 1 | 2017 | 2654 | 0.02 | Why? |
| Patient Care Team | 1 | 2020 | 3556 | 0.02 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.02 | Why? |
| Hospitalization | 1 | 2017 | 54280 | 0.02 | Why? |
| Computer Simulation | 1 | 2020 | 4982 | 0.02 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
| Dyspnea | 1 | 2018 | 3847 | 0.02 | Why? |
| Consensus | 1 | 2019 | 6345 | 0.02 | Why? |
| Multiple Organ Failure | 1 | 2015 | 1724 | 0.02 | Why? |
| Canada | 1 | 2017 | 6018 | 0.02 | Why? |
| Mortality | 1 | 2021 | 7132 | 0.02 | Why? |
| Vero Cells | 1 | 2020 | 14117 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Magnetic Resonance Imaging | 1 | 2020 | 6551 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2020 | 11304 | 0.02 | Why? |
| Models, Biological | 1 | 2020 | 4907 | 0.02 | Why? |
| T-Lymphocytes | 1 | 2020 | 6670 | 0.02 | Why? |
| Blood Glucose | 1 | 2017 | 3642 | 0.01 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.01 | Why? |
| Mice | 1 | 2017 | 21357 | 0.01 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.01 | Why? |
| Feces | 1 | 2010 | 4235 | 0.01 | Why? |
| China | 1 | 2021 | 50654 | 0.01 | Why? |
| Age Factors | 1 | 2015 | 21039 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| Depression | 1 | 2017 | 14116 | 0.01 | Why? |